The Y2 receptor agonist PYY3-36 increases the behavioural response to novelty and acute dopaminergic drug challenge in mice

International Journal of Neuropsychopharmacology

Volumn 17, Issue 3, 2014, Pages 407-419

  Stadlbauer, Ulrike ^a   Weber, Elisabeth ^a   Langhans, Wolfgang ^a   Meyer, Urs ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Amphetamine; Dopamine; GABA; Gastrointestinal hormone; Neuropeptide Y

Indexed keywords

4 AMINOBUTYRIC ACID; AMPHETAMINE; APOMORPHINE; DOPAMINE; FBC 0047; GLUTAMATE DECARBOXYLASE; PEPTIDE YY [3-36]; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL RESEARCH; CAUDATE NUCLEUS; CELL POPULATION; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; GENE PRODUCT; LOCOMOTION; MALE; MESENCEPHALON; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; STEREOTYPY;

AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BRAIN; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXPLORATORY BEHAVIOR; GLUTAMATE DECARBOXYLASE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PEPTIDE FRAGMENTS; PEPTIDE YY; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, NEUROPEPTIDE Y; STEREOTYPED BEHAVIOR; TYROSINE 3-MONOOXYGENASE;

EID: 84897876408     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713001223     Document Type: Article

References (62)

1. Adewale AS, Macarthur H, Westfall TC (2005) Neuropeptide Y induced modulation of dopamine synthesis in the striatum.Regul Pept 129:73-78.
2. Adewale AS, Macarthur H, Westfall TC (2007) Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology 52:1396-1402.
3. Arnt J, Bogeso KP, Hyttel J, Meier E (1988) Relative dopamine D1 and D2 receptor affinity and efficacy determine whether dopamine agonists induce hyperactivity or oral stereotypy in rats. Pharmacol Toxicol 62:121-130.
4. Bacopoulos NG, Bhatnagar RK (1977) Correlation between tyrosine hydroxylase activity and catecholamine concentration or turnover in brain regions. J Neurochem 29:639-643.
5. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650-654.
6. Batterham RL, Ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ, Williams SC (2007) PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450:106-109.
7. Beckmann JS, Marusich JA, Gipson CD, Bardo MT (2011) Novelty seeking, incentive salience and acquisition of cocaine self-administration in the rat. Behav Brain Res 216:159-165.
8. Belzung C, Griebel G (2001) Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125:141-149.
9. Berglund MM, Hipskind PA, Gehlert DR (2003) Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 228:217-244.
10. Berridge KC, Robinson TE (1998) What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309-369.
11. Bitanihirwe BK, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U (2010) Late prenatal immune activation in mice leads to behavioural and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 35:2462-2478.
12. Blevins JE, Chelikani PK, Haver AC, Reidelberger RD (2008) PYY(3-36) induces Fos in the arcuate nucleus and in both catecholaminergic and non-catecholaminergic neurons in the nucleus tractus solitarius of rats. Peptides 29:112-119.
13. Cabib S, Puglisi-Allegra S (1985) Different effects of apomorphine on climbing behaviour and locomotor activity in three strains of mice. Pharmacol Biochem Behav 23:555-557.
14. Chandarana K, Batterham R (2008) Peptide YY. Curr Opin Endocrinol Diabetes Obes 15:65-72.
15. Chelikani PK, Haver AC, Reidelberger RD (2005) Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 146:879-888.
16. Creese I, Iversen SD (1975) The pharmacological and anatomical substrates of the amphetamine response in the rat. Brain Res 83:419-436.
17. David HN, Ansseau M, Abraini JH (2005) Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res Brain Res Rev 50:336-360.
18. Esclapez M, Tillakaratne NJ, Kaufman DL, Tobin AJ, Houser CR (1994) Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms. J Neurosci 14(3 Pt 2):1834-1855.
19. Franklin KBJ, Paxinos G (2008) The mouse brain in stereotaxic coordinates. Amsterdam: Elsevier Academic Press.
20. Fukushiro DF, Frussa-Filho R (2011) Chronic amphetamine transforms the emotional significance of a novel but not a familiar environment: implications for addiction. Int J Neuropsychopharmacol 14:955-965.
21. Grandt D, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, Reeve JR Jr (1994) Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept 51:151-159.
22. Groenewegen HJ (2003) The basal ganglia and motor control. Neural Plast 10:107-120.
23. Groenewegen HJ, Wright CI, Beijer AV (1996) The nucleus accumbens: gateway for limbic structures to reach the motor system? Prog Brain Res 107:485-511.
24. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Møller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sørensen FB, Vesterby A, West MJ (1988) The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96:857-881.
25. Halatchev IG, Cone RD (2005) Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 1:159-168.
26. Heidbreder C, Feldon J (1998) Amphetamine-induced neurochemical and locomotor responses are expressed differentially across the anteroposterior axis of the core and shell subterritories of the nucleus accumbens. Synapse 29:310-322.
27. Kauer JA, Malenka RC (2007) Synaptic plasticity and addiction. Nat Rev Neurosci 8:844-858.
28. King PJ, Widdowson PS, Doods HN, Williams G (1999) Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J Neurochem 73:641-646.
29. Koegler FH, Enriori PJ, Billes SK, Takahashi DL, Martin MS, Clark RL, Evans AE, Grove KL, Cameron JL, Cowley MA (2005) Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 54:3198-3204.
30. Kulak A, Cuenod M, Do KQ (2012) Behavioural phenotyping of glutathione-deficient mice: relevance to schizophrenia and bipolar disorder. Behav Brain Res 226:563-570.
31. Langen M, Kas MJ, Staal WG, van Engeland H, Durston S (2011) The neurobiology of repetitive behaviour: of mice. Neurosci Biobehav Rev 35:345-355.
32. Mele A, Thomas DN, Pert A (1998) Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity. Neuroscience 82:43-58.
33. Mentlein R, Dahms P, Grandt D, Kruger R (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49:133-144.
34. Meyer U, Spoerri E, Yee BK, Schwarz MJ, Feldon J (2010) Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia. Schizophr Bull 36:607-623.
35. Narayanan NS, Guarnieri DJ, DiLeone RJ (2010) Metabolic hormones, dopamine circuits, and feeding. Front Neuroendocrinol 31:104-112.
36. Neary MT, Batterham RL (2009) Peptide YY: food for thought. Physiol Behav 97:616-619.
37. Nieoullon A (2002) Dopamine and the regulation of cognition and attention. Prog Neurobiol 67:53-83.
38. 3-36 in the mouse. J Pharmacol Exp Ther 306:948-953.
39. Peters JR, Vallie B, Difronzo M, Donaldson ST (2007) Role of dopamine D1 receptors in novelty seeking in adult female Long-Evans rats. Brain Res Bull 74:232-236.
40. Pijnenburg AJ, Honig WM, Van Rossum JM (1975) Effects of antagonists upon locomotor stimulation induced by injection of dopamine and Noradrenaline into the nucleus accumbens of nialamide-pretreated rats. Psychopharmacologia 41:175-180.
41. Pijnenburg AJ, Honig WM, Van der Heyden JA, Van Rossum JM (1976) Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur J Pharmacol 35:45-58.
42. Rebec GV, Christensen JR, Guerra C, Bardo MT (1997) Regional and temporal differences in real-time dopamine efflux in the nucleus accumbens during free-choice novelty. Brain Res 776:61-67.
43. Robbins T, Iversen SD (1973) A dissociation of the effects of d-amphetamine on locomotor activity and exploration in rats. Psychopharmacologia 28:155-164.
44. Robinson TE, Becker JB (1986) Enduring changes in brain and behaviour produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198.
45. Salahpour A, Ramsey AJ, Medvedev IO, Kile B, Sotnikova TD, Holmstrand E, Ghisi V, Nicholls PJ, Wong L, Murphy K, Sesack SR, Wightman RM, Gainetdinov RR, Caron MG (2008) Increased amphetamine-induced hyperactivity and reward in mice overexpressing the dopamine transporter. Proc Natl Acad Sci USA 105:4405-4410.
46. Schloegl H, Percik R, Horstmann A, Villringer A, Stumvoll M (2011) Peptide hormones regulating appetite-focus on neuroimaging studies in humans. Diabetes Metab Res Rev 27:104-112.
47. Smith KS, Tindell AJ, Aldridge JW, Berridge KC (2009) Ventral pallidum roles in reward and motivation. Behav Brain Res 196:155-167.
48. Smith Y, Kieval JZ (2000) Anatomy of the dopamine system in the basal ganglia. Trends Neurosci 23(10 Suppl.): S28-S33.
49. Smith-White MA, Hardy TA, Brock JA, Potter EK (2001) Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 132:861-868.
50. Spanagel R, Weiss F (1999) The dopamine hypothesis of reward: past and current status. Trends Neurosci 22:521-527.
51. Stadlbauer U, Arnold M, Weber E, Langhans W (2013a) Possible mechanisms of circulating PYY-induced satiation in male rats. Endocrinology 154:193-204.
52. 3-36 in mice induces multiple behavioural changes relevant to schizophrenia. Neuropsychopharmacology, in press (Epub ahead of print [PMID: 23748226]).
53. Stanic D, Brumovsky P, Fetissov S, Shuster S, Herzog H, Hokfelt T (2006) Characterization of neuropeptide Y2 receptor protein expression in the mouse brain. I. Distribution in cell bodies and nerve terminals. J Comp Neurol 499:357-390.
54. Strombom U (1976) Catecholamine receptor agonists: effects on motor activity and rate of tyrosine hydroxylation in mouse brain. Naunyn Schmiedebergs Arch Pharmacol 292:167-176.
55. Subramony JA (2006) Apomorphine in dopaminergic therapy. Mol Pharm 3:380-385.
56. Swerdlow NR, Koob GF (1987) Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: effects on locomotor activity mediated by nucleus accumbens-ventral pallidal circuitry. Brain Res 412:233-243.
57. Van den Heuvel DM, Pasterkamp RJ (2008) Getting connected in the dopamine system. Prog Neurobiol 85:75-93.
58. van der Loos CM (2008) Multiple immunoenzyme staining: methods and visualizations for the observation with spectral imaging. J Histochem Cytochem Society 56:313-328.
59. Vasse M, Protais P (1989) Potentiation of apomorphine-induced stereotyped behaviour by acute treatment with dopamine depleting agents: a potential role for an increased stimulation of D1 dopamine receptors. Neuropharmacology 28:931-939.
60. Vuillermot S, Weber L, Feldon J, Meyer U (2010) A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 30:1270-1287.
61. Vuillermot S, Joodmardi E, Perlmann T, Ove Ogren S, Feldon J, Meyer U (2011) Schizophrenia-relevant behaviours in a genetic mouse model of constitutive Nurr1 deficiency. Genes Brain Behav 10:589-603.
62. Wise RA (2004) Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494.